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1. Introduction 
Isotonic and isometric striated muscles contraction, as well as their extensibility and 
elasticity, are modulated by the central nervous system. Modulation at the level of 
neuromuscular synapses is also very compound, but precisely regulated, and essential for 
the induction of signals to muscle cells (Farahat & Herr 2010). The induced signal starts a 
cascade of multiple processes, necessary for sustaining muscle homeostasis. Without it, and 
also without muscle fuel utilization, muscle movement and skeletal support are deeply 
impaired. We therefore begin our description with electrochemical transmission, because its 
effects are subjected to modulation.  
2. Calcium and ATP - mediators/modulators of ion channels in myocyte 
and its contractile activity  
When a threshold potential is reached, an impulse travels along the muscle cell membrane 
and opens calcium gates in the membrane of the sarcoplasmic reticulum (SR). This is a trigger 
for the myofibrils and myofilaments located in the sarcoplasm, which turns the muscle "on”. 
A muscle stops contracting, if the impulse is no longer being transferred from the neuron to 
the sarcolemma. At that moment, calcium gates close and calcium ions move back into the 
SR. At the terminal cisternae of SR with intracellular Ca2+ stores, the ryanodine receptor 
channel isoform 1 (RyR1) is located. It is an integral component of excitation–contraction 
coupling and the receptor activation plays a key role in this process. Excitation-contraction 
coupling may be triggered by a single-pulse of electrical stimulation and results in massive 
release of Ca2+ from the SR via the RyR1 to the cytosol after depolarization of the muscle 
plasma membrane. However, skeletal muscle function in vivo is generally regulated during 
repetitive firing of short trains of action potentials (Diaz-Sylvester et al., 2008).  
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The free cytosolic Ca2+ concentration in a skeletal muscle at rest is about 120 nM and in the 
millimolar range in its intracellular stores (Eltit et al., 2011). The RyR1 is activated by an 
increase in cytosolic Ca2+ levels (with peak activation at ∼100 μM); regardless of the presence 
or absence of Mg2+/ATP, and it is called calcium induced calcium release mechanism. A 
millimolar Ca2+ concentration also inactivates per se the RyR1. The receptor may also be 
inhibited by Mg2+ or activated by caffeine and ATP. The RyR1 channel is furthermore 
modulated by ryanodine, calmodulin, 12-kDa FK-506-binding protein (FKBP12) and so-
called Homer proteins, as well as by various redox processes (Diaz-Sylvester et al., 2008; 
Eltit et al. 2011; Feng et al., 2008; Ye et al., 2012; Lawler et al., 2010). 
Variations in the intracellular levels of endogenous RyR1 modulators are relevant to 
individuals with genetic disorders of skeletal muscles associated with mutations in the 
RyR1 of SR. Some of the disorders were investigated in malignant hyperthermia (MH) 
provoked by halothane. The RyR1 becomes more susceptible to activation by halothane, 
when Mg2+ levels decrease and/or Ca2+ levels increase in the cytosol. ATP binding greatly 
increases the RyR1 activity as well. Moreover, halothane-induced RyR1 activation is 
enhanced by increases in SR Ca2+ loads. Knowledge about cytosolic modulators may help 
us understand, why decreased Mg2+ sensitivity may result in higher sensitivity to 
halothane and why RyR1 carrying MH mutations are less sensitive to Mg2+ inhibition. 
Taking into account the fact that insulin decreases intracellular Mg2+ in muscles, we are 
able to explain why MH susceptibility has been associated with increased insulin levels 
(Diaz-Sylvester et al., 2008). 
Another calcium channel is the dihydropyridine receptor (DHPR), serving as a voltage 
sensor in excitation-contraction coupling and a modulator of RyR1 through physical 
interactions (a conformational change of DHPR allosterically activates RyR1). In 
continuously depolarized skeletal muscle fibers, DHPR voltage sensors are inactivated and 
unable to initiate SR Ca2+ release. Both DHPR and RyR1 receptors bind with Triadin (a 
modulator from a family of proteins of the junctional sarcoplasmic reticulum) that is 
involved in many crucial aspects of muscle functions and E-C coupling in skeletal muscles 
(Diaz-Sylvester et al. 2008; Perez, 2011). Dihydropyridine-receptor agonists and antagonists 
can modulate both a single pulse electrical stimulation (which mainly triggers a fast calcium 
signal sensitive to RyR1) and tetanic stimulation (which induces a long-lasting, inositol 
triphosphate (IP3)-generated signal) (Lawler et al., 2010).  
Ca2+ release plays an essential role in initiating muscle contraction, increases glucose uptake 
(although its signalling is unresolved), activates numerous genes required for mitochondrial 
biogenesis, and results in ATP production in mitochondrial and cytoplasmic compartments 
during exercise (Hawley et al. 2006). A lasting contraction causes energy expenditure and 
ATP supply diminishes at some point (but usually no more than about 20 % of it even 
during very intensive exercise). This decline in ATP level causes muscle fatigue. The myosin 
heads remain bound to actin and can no longer swivel. Even when a nervous impulse is 
being transmitted to the muscle and calcium ions are still present, contraction/or strong 
contraction is not possible. Several different energy sources (phosphocreatine, muscle 
glycogen, blood glucose and fatty acids from adipose tissue) are used by myocytes to 
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maintain ATP levels in a working muscle. Although glucose is a predominant fuel for the 
muscles, diminished ATP levels in the myocyte are a signal to switch to the use of fat fuel, 
leading to an increased flux of free fatty acids and changes in the AMP/ATP ratio, 
contributing to fiber shifts. Fuel economy depends on the type of muscle fibres involved, the 
length of the physical effort and its type. There are high speed fibres which require 
carbohydrate fuels and generally used slowly contracting economical fibers with a fat-based 
aerobic metabolism (de Lange et al., 2007). 
The AMP/ATP ratio is important for the activation of AMP–activated protein kinase 
(AMPK), which stimulates energy generating processes (glucose uptake and fatty acid 
oxidation). AMPK plays a key role in controlling muscle economy, inmaintaining muscle 
homeostasis, and in inducing a cascade of events within cells in response to the ever-
changing energy charge of the cell (de Lange et al., 2007; Lira et al. 2010). 
3. Modulators of the AMP–activated protein kinase relevant in type 2 
diabetes mellitus 
AMPK was discovered in skeletal muscles in 1995 (Verhoeven et al., 1995). It is a 
heterotrimeric enzyme comprised of two catalytic (α1 or α2) subunits and two regulatory 
(1 or 2 and gamma1, gamma2, or gamma3) subunits (all are encoded by separate genes). 
AMPK activity inhibited preparations of acetyl-CoA carboxylase (ACC) and 3-hydroxy-3-
methylglutaryl-CoA reductase (HMG-CoA reductase) was first discovered. Later, it was 
noticed that AMPK activity can also be regulated by physiological stimuli, independent of 
the energy charge of the cell (like hormones and nutrients) (Lim et al., 2010; Steinberg & 
Kemp, 2009). 
AMPK is activated during contraction. Its modulation (related to the muscle energy state) 
depends on two distinct mechanisms – on an AMP-dependent pathway mediated by kinase 
LKB1 and on a Ca2+-dependent pathway mediated by the calmodulin-dependent protein 
kinase (CaMKKb). AMPK in skeletal muscles increases fatty acid oxidation and 
mitochondrial biogenesis (Lim et al., 2010). These processes require phosphorylation of the 
peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) and SIRT1. The last 
protein works as an NAD+-dependent protein deacetylase or ADP-ribosyltransferase. It also 
activates PGC-1α involved in fatty acid utilization and mitochondrial respiration (de Lange 
et al., 2007; Zhang et al., 2009). 
Mitochondrial dysfunction observed in type 2 diabetes mellitus leads to a decrease in ATP 
levels and possibly to changes in NAD+/NADH levels. It can influence 
methylenetetrahydrofolate dehydrogenase (NADP+) activity, which depends on the 
concentration of NAD+ and on the ATP/ADP ratio (Zhang et al., 2009; Mailloux & Harper, 
2010). NADH inhibits and βNAD activates AMPK, but NAD is a much weaker activator than 
AMP (we also do not know, if AMP is a direct activator). AMPK activity is modulated not only 
by nucleotides, but also by kinases, fatty acids, insulin, cytokines and reactive oxygen species 
(ROS) (Rafaeloff-Phail et al., 2004; Steinberg & Kemp, 2009; Zhang et al., 2009). 
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The major glucose transporter - GLUT4 translocation to sarcolemma, is also a result of 
AMPK-activated PGC-1α, where SIRT1 activity is required (Steinberg & Kemp, 2009). This 
pathway of glucose uptake in skeletal muscles is stimulated by palmitate (PA) (regardless of 
AMP concentrations) (Pu et al., 2011). It takes place only when skeletal muscles are exposed 
to PA for a short time. Chronic exposure to PA blocks Akt phosphorylation and inhibits 
insulin induced glucose uptake. Besides PA, linoleic, oleic, and stearic acids can stimulate 
AMPK and Akt (Pu et al., 2011).  
5-Aminoimidazole-4-carboxyamide ribonucleoside (AICAR) is another AMPK activator 
increasing GLUT4 translocation to sarcolemma and glucose uptake in rats’ skeletal muscles. 
AICAR as well as physical effort, leads to AMPK activation, which enhances a specific 
protein fatty acid translocase – FAT/CD36 in sarcolemma. Either AICAR or physical effort, 
stimulate AMPK activity in obese and type 2 diabetes mellitus, which can further enhance 
muscle lipid breakdown and the capacity for ATP generation (by the activation of 
mitochondrial fatty acid -oxidation enzymes) (de Lange et al., 2007; Steinberg & Kemp, 
2009). 
Physical effort enhances the production of ROS. ROS is produced continuously in 
mitochondria and its level is reduced by the activation of AMPK. This process has especially 
been investigated in smooth muscles, because oxidative stress (e.g. induced by free fatty 
acids) in patients with a metabolic syndrome contributes to the development of 
cardiovascular diseases (Steinberg & Kemp, 2009). 
In response to the contraction of a myocyte, interleukin-6 (IL-6) is produced and released. 
Although AMPK participates in the regulation of IL-6 release from oxidative muscle, IL-6 
significantly increases AMPK activity in myotubes as well as enhances fatty acid oxidation 
and insulin-stimulated glucose uptake. 
The effect of adiponectin on AMPK activation is not well known. AMPK is probably 
indirectly activated by increases in levels of intracellular ATP, but it is known that leptin 
directly stimulates the α2 and 2 catalytic subunits expression of AMPK in skeletal muscle. 
This occurrence correlates with enhanced fatty acid oxidation and the inhibition of 
lipogenesis. Such leptin action was reported in healthly individuals, but AMPK in obese 
individuals was not activated by leptin.  
Cytokines may also inhibit AMPK activity - tumor necrosis factor α (TNFα), which signals 
through the TNF receptor (TNFR) 1, upregulates protein phosphatase 2C (PP2C) and 
suppresses AMPK. This in turn suppresses fatty-acid oxidation and increases intramuscular 
diacylglycerol accumulation in skeletal muscle.  
AMPK is a major cellular energy sensor and a master regulator of metabolic homeostasis - 
several processes necessary for the mechanical function of muscles are controlled by 1 
enzyme. Today, AMPK is already the target of several classes of drugs used for type 2 
diabetes mellitus, including metformin and tiazolidinediones (Steinberg & Kemp, 2009; 
Zhang et al., 2009). 
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4. Myocyte modulators and insulin resistance 
Adipose tissue protects other cell tissues from “lipotoxicity”, but obesity causes 
dysregulation of lipolysis and lipid oversupply into muscles and other tissues. Adipose 
tissue also informs the brain and other tissues about this dysregulation through adiponectin, 
leptin, resistin, IL-6 and TNFα (Steinberg & Kemp, 2009). Not only is the adipose tissue 
recognized as an endocrine organ, it also produces modulators relevant for IR. There is also 
the hepatic insulin sensitizing substance (HISS), which after being released from the liver, 
acts on skeletal muscles to stimulate glucose storage in the form of glycogen. The 
intramyocytal signaling cascade in type 2 diabetes mellitus is impaired due to insulin 
modulation by HISS and in the future we will probably differentiate these two types of 
diabetes mellitus in the GP’s surgery (Lautt et al., 2010). 
It is clear that insulin activates the pathway of kinase Akt and hampers AMPK activity, but 
despite the developing knowledge about AMPK, we still do not know enough about IR. 
When skeletal muscles become unable to switch between glucose and fatty acid use, the 
cause of glucose uptake and utilization is dramatically lessened.   
There is evidence that nitric oxide (NO) is a modulator of insulin action and insulin resistance 
is linked to inducible NO synthase (iNOS) induction in skeletal muscle cells (and in other 
insulin target cells as well). An increased expression of multiple inflammatory cytokines 
(TNFα, interferon-c, IL-6, and IL-1) observed in obesity has to induce iNOS as it was shown 
on an animal model of acute systemic inflammation that iNOS in muscle (also in liver and 
adipose) tissue was induced by the administration of the endotoxin lipopolysaccharide (LPS). 
Cytokines modulate glucose transport in the skeletal muscle by inducing the expression of 
iNOS. Moreover, a high-dose of aspirin improves glucose metabolism in patients with type 2 
diabetes mellitus. There is also genetic evidence that iNOS mediates skeletal muscle IR in 
obese high-fat fed mice and that the induction of iNOS in skeletal muscle modulates whole-
body glucose metabolism (Cha et al., 2011; Soskić et al., 2011).  
AMPK phosphorylates and activates NOS, and physiological levels of NO can stimulate 
glucose uptake and oxidation in human skeletal muscles, but the meaning of NOS for 
glucose homeostasis is still cloudy (Steinberg & Kemp, 2009). Physical effort increases NOS 
activity and the expression of neuronal (nNOS) and endothelial (eNOS) NOS. There is some 
evidence that mitochondrial respiration in myocytes is inhibited by NOS activity. NO 
donors, such as sodium nitroprusside, raise skeletal muscle cGMP content and increase 
glucose uptake in rats, but the AICAR effect is not blocked by NOS inhibitors (McConell & 
Wadley, 2008). Chronic administration of NOS inhibitors (monomethylarginine - L-NAME) 
in drinking water decreases glucose tolerance in rats (Balon et al., 1999).  
Another therapeutic target in insulin resistance may be stearoyl-CoA desaturase (SCD). The 
major product of SCD - oleic acid, may play an important role in the regulation of 
intracellular ceramide synthesis, which is recognized as an insulin-desensitizing lipid 
molecule. The lack of the SCD1 gene increases the rate of fatty acid ß-oxidation - it results in 
a decrease of free fatty acids and long-chain fatty acyl-CoAs content in the soleus and red 
gastrocnemius SCD1-/- mice models. The AMPK pathway is also involved in this process. It 
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increases this enzyme’s phosphorylation and contributes to an increase of insulin sensitivity 
in the muscles. The expressions of a protein-tyrosine phosphatase 1B (PTP-1B) is down 
regulated in the case of SCD1 deficiency. This expression is responsible for the sustained 
insulin receptor autophosphorylation (Dobrzyn & Dobrzyn, 2006; Dobrzyn et al., 2010).  
PUFA, cholesterol, vitamin A, hormonal signals (e.g. insulin, glucagon), environmental and 
developmental factors (temperature changes, metals), alcohol, thiazolinediones, peroxisomal 
proliferators modulate stearoyl-CoA desaturase (SCD) expression in adipose tissue and liver. It 
is proven that some of these compounds are able to modulate SCD by catalyzing the synthesis 
of monounsaturated fatty acids (mainly oleate and palmitoleate acids) in muscles. Glucose is 
probably the most important modulator of SCD expression in the skeletal muscle. Its long-
term oversupply increases SCD expression and enzyme activity - it leads to fast and specific 
changes in fatty acid metabolism. Further investigations of SCD modulators may be relevant, 
because stress and inflammatory stimuli can also modulate Transcriptional regulation of SPT, 
which is the first committed step in de novo ceramide synthesis (Dobrzyn & Dobrzyn, 2006).  
There is also evidence that insulin resistance and type 2 diabetes mellitus are linked to the 
reduction of insulin receptor substrate (IRS-1) expression, and the impairment of PI3K and 
kinase Akt activity in skeletal muscle. Impaired insulin-mediated glucose transport is a 
characteristic defect in type 2 diabetes mellitus. There is normal expression of the human 
GLUT4 gene in type 2 diabetes mellitus, but a cause of insulin resistance is searched out in 
traffic of this glucose transporter to sarcolemma. The translocation of GLUT4 to the 
membrane increases its glucose permeability. GLUT4 intracellular redistribution is directly 
linked to a signaling protein known as AS160 which may be activated by both the insulin 
pathway and AMPK. Hampering of the Akt substrate of 160 kDa (AS160), phosphorylation 
(as a result of Akt phosphorylation in the position of Thr308) diminishes the activity of 
AS160. Impaired insulin-stimulated phosphorylation of AS160 has been discovered in 
patients with insulin resistance or/and type 2 diabetes mellitus (Treebak et al., 2007). 
When no muscles stimulation exists, then only about 10% of GLUT-4 transporters are located 
in the sarcolemma, but their amount increases to 50% after 2-3 minutes of stimulation with 
insulin. Relocation of GLUT4 from an intracellular pool of myocytes to its membrane is 
phosphorylated and activated not only by insulin (associated with the activation of kinase 
PI3K), but also may be activated by IGF1, EGF and AICAR. NO induces the upregulation of 
GLUT4 mRNA (by the AMPK dependent pathway) (Wang et al., 1996; Russell et al., 1999).  
The role of NO in a skeletal muscle has still not been investigated enough. The interaction of 
AMPK, NOS enzymes, and NO levels in skeletal muscles is intriguing (AMPK activates 
eNOS and nNOS, but AMPK activation inhibits iNOS expression). We think that the 
significance of the effect of SCD1 deficiency/downregulation on lipid metabolism and 
insulin sensitivity in the skeletal muscle is underrated, as lipids are transported through 
sarcolemma (Steinberg & Kemp, 2009). 
The last investigation showed that dysregulation in PA uptake and reduced CD36 protein 
level in murine myocyte are recognized as a reason of metabolic complications analogous to 
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“the cardio-metabolic syndrome” in patients treated with a protease inhibitor of the human 
immunodeficiency virus (Richmond et al., 2010).  
It is a real challenge to establish a cause of diabetes mellitus type 2, which is probably 
multifactorial. One of those factors is a sedentary lifestyle, another one is obesity and a high 
fat calorie diet, they induce inflammatory cytokines and reduce insulin signaling. This 
subsequent loss of homeostatic signaling yields a low heat shock proteins (HSP) state 
(Atalay et al., 2009). The HSPs respond to a wide variety of stress factors (e.g. elevated 
temperature, hypoxia, altered pH) and first studies in patients with diabetes mellitus type 2 
revealed that hot-tub therapy is able to improve glycemic control (Gupte et al., 2009, as cited 
in Hooper, 1999). Later it was described that HSP90 maintains the Akt and plays an 
important role in the regulation of glucose transport mediated by insulin (Atalay et al. 2009, 
as cited in Sato S. et al. 2000). Moreover, a lower level of HSP72 was found in skeletal 
muscles of patients with type 2 diabetes and some HSPs were strongly induced in skeletal 
muscle with physical exercises especially in fast-twitch muscles (Atalay et al. 2009, as cited 
in Bruce, 2003 and Kurucz, 2002). A recent study demonstrated that heat treatment protects 
skeletal muscles in rats from a high-fat diet–induced insulin resistance and provided strong 
evidence that HSP induction in skeletal muscles could be a potential therapeutic treatment 
for obesity-induced insulin resistance (Gupte et al., 2009). 
The HSP60 expression improves mitochondrial dysfunction observed in skeletal muscles of 
patients with type 2 diabetes as measured by oxidative capacity, with a high-fat diet in parallel 
with increased mitochondrial protein expression (Gupte et al., 2009). Also thiazolidinediones 
increase expression of an array of mitochondrial proteins in diabetic mousses (it also concerns 
PGC1α, the master regulation of mitochondrial biogenesis) (Cantó et al., 2009) and we think 
that mitochondria are a primary target of heat therapy from oxidative stress. 
Recently, BGP15 (an HSP inducer) was found as a potent insulin sensitizer, which increases 
muscle glucose utilization (Literáti-Nagy et al. 2009). It protects the mitochondrial membrane 
against oxidative damage by the activation of PI-3-kinase – Akt pathway. This well-known 
cytoprotective pathway is suppressed by Poly (ADP-ribose) polymerase (PARP), which can 
induce rapid cellular NAD+ and ATP pool depletion leading to mitochondrial dysfunction. 
The small molecule BGP15 is an inhibitor of PARP presented in eukaryotes and may be a 
novel strategy for therapies of insulin resistance (Halmosi et al. 2001)  
We were able to find more evidence that our surroundings also have input in type 2 diabetes 
mellitus etiology. Bisphenol-A (BPA), a component of polycarbonate plastics and epoxy resins, 
widely used in multiple consumer products like plastic food/fluids containers is commonly 
recognized as a disruptor of glucose homeostasis, which provokes hyperinsulinemia and 
insulin resistance. The measurable levels of this synthetic estrogen were reported in human 
serum, urine, breast milk, fetal plasma, and placental tissue. It probably modulates the glucose 
transporter GLUT4 through two estrogen receptors (ERα and ERβ). Studies showed that 
elevated BPA level was associated with elevated hemoglobin A1c (HbA1c). Also higher 
urinary BPA level was found to be associated with diabetes type 2 diabetes mellitus 
independently of traditional diabetes risk factors (Lang et al., 2008; Vandenberg et al., 2007; Li 
et al., 2012). On the other hand, α-lipoic acid (LA) (found abundantly in green vegetables) 
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affects the insulin-signaling cascade and protects myocyte from oxidative stress-induced 
insulin resistance (Maddux et al., 2001). Also green and black teas suppress insulin resistance 
by retaining the expression of GLUT4 in skeletal muscle. Epidemiological data suggests that 
drinking green tea is negatively associated with type 2 diabetes (Anderson & Polansky 2002; 
Nishiumi et al 2010; Yan et al. 2012). Green tea reduces oxidative stress in animal adipocytes 
(Yan et al. 2012), it also decrease ROS content of cultured mouse myotubes (Buetler et al., 
2002), but we have not yet investigated, if green tea protects myocytes from oxidative stress-
induced insulin resistance. Several international prospective studies show a protective effect of 
coffee on the development of type 2 diabetes (Kempf & Martin 2010). We focused on the 
modulators crucial for peripheral insulin resistance, but impaired pancreatic glucose sensing is 
involved in etiology of diabetes mellitus type 2 as well. It is a genetically complex chronic 
disease, but lifestyle changes can delay progression to diabetes, even in high-risk individuals, 
for at least a decade (Cho et al. 2012; Knowler WC et al. 2009). 
5. Muscular contraction – underestimated modulator 
Physical exercise is a potent stimulus for increasing glucose uptake in the complete absence 
of insulin. This mechanism may be modulated by AMPK, Akt/protein kinase B 
phosphorylation, NO and Ca2+/calmodulin-dependent protein kinase (CaMK) and protein 
kinase C (PKC) and is initiated by acute exercise. This is a short–lived effect, which 
disappears in 16-48 h. However, repeated physical exercise results in an increase in insulin 
action, sustain in skeletal muscle of patients with insulin resistance and type 2 diabetes 
mellitus. This improvement in insulin sensitivity is related to increasing AS160 
phosphorylation, expression and/or activity protein kinase B (Akt) and AMPK (Hawley & 
Lessard, 2008; Ismail-Beigi, 2012; Cahová et al., 2007; Wasserman et al., 2011).  
Exercise training results also in glucose uptake through an increase in the level of GLUT4 
trafficking. Training may cause increasing 30% of GLUT4 in sarcolemma of patients with type 
2 diabetes mellitus and 20% of GLUT4 in control group (Wasserman et al., 2011). We outlined 
above, how muscle contraction my improve insulin sensitivity by increased lipid oxidation. 
There is also clinical evidence that physical activity (150 min/week) and diet-induced weight 
loss of 5–7% are able to reduce the risk of progression from impaired glucose tolerance to 
type 2 diabetes mellitus. Therefore, very recently the guidance in type 2 diabetes mellitus has 
been changed – more attention is given to muscle contraction as a modulator, which has 
become a key part of type 2 diabetes mellitus self-management (Sigal et al., 2006).  
6. Conclusion 
Type 2 diabetes mellitus is still a challenge for biochemists, clinicians and epidemiologists. It 
has been assessed that 23.6 million people lived in the US in 2007 with diagnosed and 
undiagnosed diabetes (7.8% of the general population). There are forecasts that 366 million 
people in the world will live with type 2 diabetes mellitus in 2030 (Zhang et al., 2009).  
Recently, physical exercise has been recognized by health organizations as an undoubted 
modulator of glucose uptake in skeletal muscles. We hope that awareness of this fact will be 
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created by promotion in the GP’s surgery and through mass media. Muscle contraction as a 
modulator of GLUT4 expression, which also improves insulin signal transduction at the level 
of PI3K and AS160, and activates AMPK, is able not only to diminish a dose of oral medicine 
in type 2 diabetes mellitus, but also to influencethe future of patients with insulin resistance. 
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